logo-loader
viewNeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals taking a different approach to treat Alzheimer's Disease

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) Chief Scientific Officer Anton Uvarov sat down with Proactive at the 2019 BIO Investor Forum in San Francisco. 

The Australian-based biotech company is developing peptide therapeutics to treat neurodegenerative conditions.

Quick facts: NeuroScientific Biopharmaceuticals Ltd

Price: 0.23 AUD

ASX:NSB
Market: ASX
Market Cap: $18.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

DomaCom's Arthur Naoumidis discusses acquisition of first Rent-to-Own property

DomaCom Ltd's (ASX:DCL) Arthur Naoumidis caught up with Proactive's Andrew Scott following the news it's acquired the first property for its new, innovative Rent-to-Own product in the Melbourne suburb of Moonee Ponds. The one-bedroom apartment in the Mason Square development was acquired for...

1 day, 1 hour ago

2 min read